Study of EQU-001 for Uncontrolled Focal Onset Seizures
Status:
Not yet recruiting
Trial end date:
2026-11-01
Target enrollment:
Participant gender:
Summary
This study is a Phase 2 multinational, double-blind, placebo-controlled, randomized (1:1:1),
efficacy and safety study of adjunctive EQU-001 for the treatment of focal onset seizures in
subjects aged 18 to 65 years, who have been diagnosed with epilepsy according to
International League Against Epilepsy (ILAE) Classification of the Epilepsies 2017 criteria
This study is designed to test the efficacy and safety of EQU-001 20 mg and 60 mg as compared
with placebo as an add-on anti-seizure medication (ASM) in subjects with uncontrolled focal
onset seizures.
The treatment portion of the study will be comprised of a 4-week double-blind medication
activation period and a 12-week double-blind maintenance period.